N/A N=230 Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)
Non Small-cell Lung Cancer
Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=304 A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
Tumors Characterized by Genetic Abnormalities of ALK
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=1,066 An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants
N/A N=161 Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Non-Small-Cell Lung Carcinoma
Primary: Number of Participants Classified According to Treatments Received for Anaplastic Lymphoma Kinase Positive-non-Small Cell Lung Cancer (ALK + NSCLC) in Sequence — 103; 8…
Phase 3 N=347 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
N/A N=62 Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance
Non-Small Cell Lung Cancer
Primary: Prevalence of ALK Fusion — 27 Participants
N/A N=73 Descriptive Observational Study ALK-2016-CPHG
NSCLC · Crizotinib · ALK Gene Rearrangement or ROS1 Gene Rearrangement
Primary: Age: Line of Treatment — 62.3; 63.1; 56.5; 64.3 Years
Phase 2 N=124 LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) by Investigator Assessment — 67.7 Percentage of participants
Phase 2 N=6 AUY922 for Advanced ALK-positive NSCLC
Non Small Cell Lung Cancer
Primary: Objective Response Rate — 0 Participants
N/A N=449 Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement — 8.69 percentage of participants
Phase 2 N=364 A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Primary: Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0; 0 Participants
Phase 3 N=207 A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
NSCLC (Non-small Cell Lung Cancer)
Primary: Progression-Free Survival (PFS) Based on IRR by Treatment Arm — 11.1; 6.8 Months — p=<0.0001
Phase 1 N=40 Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
ALK-activated Tumors
Primary: Incidence Rate of Dose Limiting Toxicities (DLTs) Occurring During First Cycle of Treatment — 0; 0; 0; 1 Participants
Phase 3 N=376 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) — 16.6; 8.1 Months — p=<0.001
Phase 2 N=103 LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Non-Small Cell Lung Cancer
Primary: Primary Pharmacokinetics (PK) Parameters of of LDK378 After Daily Oral Dose: AUClast, AUC0-24h, AUCinf — 10100; 3940; 11100 ng*hr/mL
N/A N=4,240 Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
Lung Neoplasms
Primary: Number of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Biomarker — 45; 1346; 21; 38 Participants
N/A N=572 Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Non-Small Cell Lung Cancer
Primary: Eastern Cooperative Oncology Group (ECOG) Quality of Life Score: ALK Treatment and ROS1 Sub-study Only — 35; 11; 43; 29 Participants
N/A N=549 Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
ALK-positive NSCLC
Primary: Overall Survival (OS): Based on Treatment Cohort Groups — 1.94; 2.30; 4.56; 2.94 Years
Phase 2 N=140 LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 Per Investigator Assessment — 40.7 Percentage of participants
Phase 2 N=20 LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Non-Small-Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 by Investigator Assessment — 25.0 Percentage of participants
Phase 2 N=122 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Recurrent Childhood Anaplastic Large Cell Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Neuroblastoma
Primary: Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib — 280 mg/m²/dose BID
Phase 2 N=137 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Lymphoma, Large-Cell, Anaplastic · Carcinoma, Non-Small-Cell Lung
Primary: Recommended Phase 2 Dose (RP2D) of Brigatinib — NA mg
Phase 2 N=47 A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase I — 0; 0; 0; 0 participants
Phase 3 N=343 A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Non Squamous Lung Cancer
Primary: Progression-Free Survival (PFS) Based on IRR — 10.9; 7.0 months — p=<0.0001
Phase 2 N=3 Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
Lung Cancer, Nonsmall Cell
Primary: The Number of Participants With an Objective Tumor Response Rate — 3 participants
Phase 2 N=138 A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Non-Small-Cell Lung Carcinoma
Primary: Recommended Phase 2 Dose (RP2D) of Alectinib
Phase 2 N=131 Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Advanced Solid Tumors · Non-small Cell Lung Cancer
Primary: Maximum Tolerated Dose — 250 mg
Phase 2 N=127 Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
Non Small Cell Lung Cancer · ROS1 Proto Oncogene · Crizotinib
Primary: Independent Radiology Reviewed Overall Objective Response (ORR) — 88 Participants
Phase 2 N=156 A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
ALK-positive Non-small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Per Investigator Assessment — 35.7; 30.0; 50.0; 59.1 Percentage of participants
Phase 4 N=71 Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Carcinoma · Non-Small-Cell Lung
Primary: Percentage of Participants With Confirmed Overall Objective Response (OR) as Per Independent Central Review (ICR) as Assessed by RECIST v1.1 — 42.3 Percentage of…